Systemic vascular resistance and fluid status in patients with decompensated liver cirrhosis with or without functional renal failure in Egypt
Keywords:
Fluid status, Hepatorenal syndrome (HRS), Inferior vena cava (IVC) collapsibility, Liver cirrhosis, Systemic vascular resistance (SVR)Abstract
Background: Functional renal failure and cardiovascular dysfunction are common complications of liver cirrhosis. This study aimed to evaluate cardiac performance, systemic vascular resistance (SVR) and fluid status in patients with decompensated liver cirrhosis either with or without functional renal failure.
Methods: Sixty patients diagnosed as having decompensated liver cirrhosis were divided into two groups. Group 1 included 30 patients with decompensated liver cirrhosis with ascites and with creatinine values ≤ 1.5 mg/dl. Group 2 included 30 azotemic decompensated cirrhotic patients with diagnostic criteria of hepatorenal syndrome (HRS). Also, 20 healthy subjects, of matched age and sex to the Group 1 and Group 2 patients, were included in the study as the control group. All patients and normal controls were subjected to clinical examination, laboratory evaluation, ECG, abdominal ultrasonography and echocardiographic studies.
Results: The echocardiographic and ECG data showed significant increase in LAD (P<0.01, P<0.01), AoD (P<0.05, P<0.01), interventricular septum thickness (IVST) (P<0.01, P<0.01), posterior wall thickness (PWT) (P<0.01, P<0.01), EDD (P<0.01, P<0.01), ESD (P<0.05, P<0.01), left ventricular (LV) mass (P<0.01, P<0.01), and Corrected QT (QTc) (P<0.01, P<0.01) interval with significant decrease in SVR (P<0.01, P<0.01). Additionally, there was significant decrease in IVC diameter in both patients groups compared to the control group (P<0.01, P<0.01).
Conclusion: Patients with decompensated liver cirrhosis have low SVR, and Doppler echocardiography provides an easy noninvasive tool to assess this finding. Also, these patients demonstrate small inferior vena cava (IVC) diameter with normal collapsibility, which indicates low effective plasma volume. Measuring IVC diameter and collapsibility are of value in the prediction of intravascular fluid status in liver cirrhosis. This is especially true with renal dysfunction. Early addition of oral vasoconstrictors in decompensated patients may correct the SVR and circulatory dysfunction and hinder HRS occurrence.
References
Dalmau-Bueno A, Garcia-Altes A, Marí-Dell’olmo M. et al. Trends in socio-economic inequalities in cirrhosis
mortality in an urban area of Southern Europe: a multilevel approach. J Epidemiol Community Health
;64:720–727.
Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital
Stat Rep 2009;57:1–134.
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part III: Liver, biliary tract, and
pancreas. Gastroenterology 2009;136:1134–1144.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838–851.
Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48:2064–77.
Cynthia D,Tsien DC, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013;62:131- 137.
Fernández-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver
cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989;97:1304-12.
Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney
dysfunction. Hepatology 1993;17:788-93.
Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume
expansion. J Clin Invest. 1967; 46:1894-906.
Lebrec D. Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther. 2004;20 Suppl
:65-7.
Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in
liver disease. Heart 2002;87:9–15.
Pozzi M, Redaelli E, Ratti L, et al. Time-course of diastolic dysfunction in different stages of chronic HCV
related liver diseases, Minerva Gastroenterologica e Dietologica 2005; 51( 2):179–186,
Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abdnormalities in patients with
cirrhosis, Journal of Hepatology 2006;44(5):994–1002.
Goitein O, Matetzky S, Beinart R, et al. Acute myocarditis: noninvasive evaluation with cardiac MRI and
transthoracic echocardiography. American Journal of Roentgenology 2009;192(1):254–258.
Valeriano V, Funaro S, Lionetti R, et al. Modification of cardiac function in cirrhotic patients with and without
ascites, American Journal of Gastroenterology 2000;95(11): 3200–3205.
Noninvasive measurement of systemic vascular resistance using Doppler echocardiography. American Society
of Echocardiography 2004;17(8):834-838.
Goldflam K, Saul T, Lewiss R. Focus On: Inferior Vena Cava Ultrasound. ACEP News, June 2011.
Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal
syndrome in cirrhosis. Gut 2007;56:1310-1318.
Goldman MJ. Principles of clinical electrocardiography. 8th ed. Los Altos: Lange Medical cary,1973;24-28.
Bernardi M, Calandra S, Colantoni A, et al. Q-T Interval Prolongation in Cirrhosis: Prevalence, Relationship
With Severity, and Etiology of the Disease and Possible Pathogenetic Factors. Hepatology 1989;27:28-34.
Gottdiener J.S., Bendnarz I., Devereaux R, et al. American Society of Echocardiography recommendations for
use of echocardiography in clinical trials. Journal of American Society of Echocardiography 2004;17:1086–
Teichholz LE, Kreulen T, Herman MV, Gorlin D. Problems in echocardiographic volume determinations. Am J
Cardiol. 1976;37(1):7-11.
Lubien E, DeMaria A, Krishnaswamy P, et al. : Utility of Brain Natriuretic Peptide in Detecting Diastolic
Dysfunction : Comparison With Doppler Velocity Recordings. Circulation 2002; 105:595-601.
Mandelbaum A, Ritz E. Vena cava diameter measurement for estimation of dry weight in haemodialysis
patients. Nephrol Dial Transplant.1996;11(2):24-27.
Brennan JM, Blair JE, Goonewardena S, et al. Reappraisal of the use of inferior vena cava for estimating right
atrial pressure. J Am Soc Echocardiogr. 2007;20:857–861.
Feissel M, Michard F, Faller JP, Teboul JL. The respiratory variation in inferior vena cava diameter as a guide
to fluid therapy. Intensive Care Med 2004; 30:1834–1837.
Weekes A, Tassone H, Babcock A, et al. Comparison of serial qualitative and quantitative assessments of caval
index and left ventricular systolic function during early fluid resuscitation of hypotensive emergency
department patients. Acad Emerg Med 2011;18:912–921.
Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57: 268-278.
Lebrec D. Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther. 2004;20(3):65-7.
Mandal L, Mandal SK, Bandyopadhyay D, Datta S. Correlation of portal vein diameter and splenic size with
gastro-oesophageal varices in cirrhosis of liver. Journal Indian Academy of Clinical Medicine 2011;12(4):266- 270.
Sudha Rani KVL , Sudarsi B, Siddeswari R, Manohar S. Correlation of Portal Vein Size with Esophageal
Varices Severity in Patients with Cirrhosis of Liver with Portal Hypertension. International Journal of
Scientific and Research Publications 2015;5(1): 1-5.
Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010;53:179-190.
Cavasi A, Cavasi E, Grigorescu M, Sitar-Taut A. Relationship between NT-proBNP and Cardio-Renal
Dysfunction in Patients with Advanced Liver Cirrhosis. J Gastrointestin Liver Dis. 2014;231:51-56.
Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
Hepatology 2008;48(3):1002-1006.
Bengus A, Babiuc RD. Hyponatremia – predictor of adverse prognosis in cirrhosis. Journal of Medicine and
Life 2012;5.2 :176-8.
Gaglio P, Marfo K, and Chiodo J. Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the
Vasopressin V2-Receptor Antagonist Tolvaptan. Dig Dis Sci. 2012;57(11): 2774–2785.
Cirrhosis From Wikipedia, the free encyclopedia. This page was last modified on 17 March 2015, at 20:31.
Available at http://en.wikipedia.org/wiki/Cirrhosis.
FisherEM, Brown DK. Hepatorenal Syndrome Beyond Liver Failure AACN Advanced Critical Care 2010;
(2):165–184.
Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non- alcoholic cirrhosis. J Hepatol 1995;22: 326–332.
Wong F, Girgrah N, Graba J, et al. The cardiac response to exercise in cirrhosis. Gut 2001;49:268–275
Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol.
;167:1101–1108.
Schrier RW, Ecder T, Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation:
implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001;68: 350–361.
Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the
molecule. Hepatology 2006;43:121–131.
Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM, et al. Ana¬tomical cardiac alterations in liver
cirrhosis: an autopsy study. Ann Hepatol 2011;10:321–6.
Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathpphysiological review of circulatory dysfunction in
liver disease. Heart 2002;87: 9-15.
Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J
Gastroenterol 1996;31:279-84.
Ginès P. Left ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic
hemodynamics and renal dysfunction. Journal of Hepatology 2013;58(1):51-57.
Baik S, Fouad T, Lee S. Cirrhotic cardiomyopathy. Orphanet Journal of Rare Diseases 2007;2:15-19.
Sawant P, Vashishtha C, Nasa M. Management of Cardiopulmonary Complications of Cirrhosis. International
Journal of Hepatology 2011;1-11-15.
Gaduputi V, Abdulsamad M, Sakam S, Abbas N, Tariq H, Ihimoyan A. Systemic vascular resistance in
cirrhosis: a predictor of severity? Hepatic Medicine: Evidence and Research 2014;6: 95–101.
Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic
circulation in portal hypertensive rats. Am J Physiol. 1999;276:1043–1051.
Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet.
;337(8744):776–778.
Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis:
relationship to endotoxemia. Hepatology. 1993;18(5):1139–1143.
Tarantino G, Citro V, Conca P, et al. What are the implications of the spontaneous spleno-renal shunts in liver
cirrhosis? BMC Gastroenterol. 2009;9:89-98.
Tarantino G, Citro V, Esposito P, et al. Blood ammonia levels in liver cirrhosis: a clue for the presence of
portosystemic collateral veins. BMC Gastroenterol. 2009;9:21-24.
De las Heras D, Fernández J, Ginès P, et al. Increased carbon monoxide production in patients with cirrhosis
with and without spontaneous bacterial peritonitis. Hepatology 2003;38(2):452–459.
Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cir¬rhotic patients. Relationship with portal
hypertension and changes after intestinal decontamination. Gastroenterology 1992;102(1):303–309.
Ebrahimkhani MR, Mani AR, Moore K. Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a
hypothesis. Gut. 2005;54(12):1668–1671.
Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279–1290.
Schrier RW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation
of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–1157.
Gaduputi V, Abdulsamad M, SakamS, Abbas N, Tariq H, Ihimoyan A. Systemic vascular resistance in
cirrhosis: a predictor of severity? Hepatic Medicine: Evidence and Research 2014;6:95–101.
Davenport A. AKI in a Patient with Cirrhosis and Ascites. Clinical Journal of the American Society of
Nephrology. 2012;7(12):2041-2048.
Kitamura H, Kobayashi C. Impairment of change in diameter of the hepatic portion of the inferior vena cava: a
sonographic sign of liver fibrosis or cirrhosis. J Ultrasound Med 2005; 24:355–359.
Seif D, Mailhot T, Perera P, Mandavia D, Caval Sonography in Shock. A Noninvasive Method for Evaluating
Intravascular Volume in Critically Ill Patients. J Ultrasound Med 2012; 31:1885–1890.
Yang K, Correlating IVC. Measurements with Intravascular Volume Changes at Three Distinct Measurement
Sites. A Thesis submitted to the University of Arizona College of Medicine 2014.
Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S. Acute effects of the oral administration of
midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with
ascites. Hepatology 1998;28:937–943.
Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with
midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213–221.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
